The FDA has accepted AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's Biologics License Application for priority review for their drug datopotamab deruxtecan, also known as Dato-DXd, for the treatment of ...

The Health Secretary is looking at changing the law regarding compensation for people harmed by Covid vaccines amid concern ...

Synthego, a leading supplier of CRISPR solutions, has entered a strategic licensing agreement with global biopharmaceutical company AstraZeneca. This agreement grants Synthego a global license to ...

Daiichi Sankyo and AstraZeneca’s (AZN) biologics license application for datopotamab deruxtecan has been accepted and granted priority review ...

Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending ...

NDAQ:AZN) AstraZeneca PLC Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AZN ...

AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales. It has several candidates ...

AstraZeneca has been taking a wider role in Vietnam’s healthcare sector to help expand access to quality healthcare.

As we enter 2025, many growth stocks are trading at high valuations and could be running out of room to rise in the near term ...

We recently compiled a list of the 10 Best FTSE Dividend Stocks To Buy Now. In this article, we are going to take a look at ...

Oppenheimer initiated coverage of Compugen (CGEN) with an Outperform rating and $4 price target. With a sole oncology focus, Compugen is ...